According to Fortune Business Insights, the global antibiotic infusion therapy market size was valued at USD 35.78 billion in 2025. The market is projected to grow from USD 37.75 billion in 2026 to USD 60.42 billion by 2034, exhibiting a CAGR of 6.05% during the forecast period. North America dominated the antibiotic infusion therapy market with a market share of 38.71% in 2025.
Antibiotic infusion therapy involves administering antibiotics intravenously to treat bacterial infections that require targeted, reliable, or closely monitored treatment. It is commonly used for patients with severe infections, complicated bacterial conditions, and infections that cannot be managed effectively with oral medications. The antibiotic infusion therapy market is gaining importance as healthcare providers focus on effective infection management, improved patient outcomes, and access to specialized treatment services. Growing demand for hospital-based care, advances in infusion technologies, and the expansion of outpatient and home-based treatment are supporting market development in 2026.
Continue reading for more details:
https://www.fortunebusinessinsights.com/antibiotic-infusion-therapy-market-117934
The antibiotic infusion therapy market can be segmented based on drug class, indication, route of administration, end user, and distribution channel. By drug class, the market includes cephalosporins, penicillins, carbapenems, aminoglycosides, glycopeptides, and other antibiotics. These drug classes are selected according to the suspected or confirmed bacterial pathogen, infection severity, patient characteristics, and antimicrobial susceptibility results. Healthcare professionals determine the appropriate antibiotic based on clinical guidelines and the need to achieve effective treatment while minimizing unnecessary antibiotic exposure.
Based on indication, the market covers bloodstream infections, respiratory infections, skin and soft tissue infections, bone and joint infections, urinary tract infections, and other bacterial conditions requiring intravenous treatment. Patients with severe or complicated infections may require infusion therapy when rapid and dependable delivery of medication is clinically appropriate. The treatment approach depends on infection characteristics, patient response, and the availability of suitable alternative therapies.
By route of administration, intravenous infusion is the principal method used to deliver antibiotics directly into the bloodstream. Treatment may be administered through conventional intravenous access or specialized vascular access devices, depending on the duration and clinical requirements of therapy. Infusion pumps and associated administration equipment help healthcare professionals control medication delivery and support consistent treatment protocols.
By end user, the antibiotic infusion therapy market includes hospitals, specialty clinics, ambulatory infusion centers, and home healthcare settings. Hospitals remain important because they manage severe infections and patients requiring continuous clinical monitoring. Ambulatory infusion centers provide treatment for eligible patients who do not require hospital admission, while home infusion services support selected patients who can safely receive treatment outside healthcare facilities. Distribution channels include hospital pharmacies, retail pharmacies, specialty pharmacies, and other providers supplying prescribed infusion medications and related products.
The antibiotic infusion therapy market is supported by the ongoing need to treat severe and complicated bacterial infections. Intravenous antibiotics are important in clinical situations where patients require prompt treatment, cannot tolerate oral medication, or have infections that require closely supervised antimicrobial administration. Hospitals and healthcare providers continue to depend on infusion therapy for selected patients with serious infections, supporting demand for antibiotics and associated administration equipment.